BioArctic awarded patent by EPO for potential Alzheimer's antibodies

By The Science Advisory Board staff writers

January 27, 2021 -- The European Patent Office (EPO) has granted Swedish-based biopharmaceutical company BioArctic patent EP 2, 558, 968 B1 for its novel antibodies that could be developed to treat Alzheimer's disease.

The antibodies target a truncated form of amyloid beta (pE3-Aβ) and are part of BioArctic's AD1503 program. Monomers of pE3-Aβ are highly prone to aggregate, leading to the formation of harmful amyloid beta aggregates, which cause the symptoms associated with Alzheimer's disease. The company believes that focusing on other forms of amyloid beta species in the Alzheimer's disease cascade can open the door for future treatment possibilities.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.